Akèy › Maladi Crohn › North Carolina
Etid klinik pou Maladi Crohn nan North Carolina
20 etid pou Maladi Crohn ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- ak 1 plis
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- ak 3 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
Ap rekriteFaz 2
Laj 18 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT06226883A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 4
Laj 18 ak plis · Fanm · Mizajou Aug 28, 2026 · NCT07654751A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekrite
Laj 18 a 44 · Fanm · Mizajou Jul 14, 2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
Ap rekriteEtid obsèvasyon
Laj 1 a 18 · Tout sèks · Mizajou Apr 17, 2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
Ap rekriteEtid obsèvasyon
Tout laj · Fanm · Mizajou Jul 17, 2025 · NCT04846959Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.